Jason Farrar
Concepts (657)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Leukemia, Myeloid, Acute | 14 | 2024 | 192 | 3.200 |
Why?
| Anemia, Diamond-Blackfan | 12 | 2021 | 12 | 2.760 |
Why?
| Dengue | 18 | 2017 | 22 | 2.270 |
Why?
| Typhoid Fever | 14 | 2017 | 18 | 2.010 |
Why?
| Mutation | 18 | 2023 | 1504 | 1.870 |
Why?
| Influenza, Human | 16 | 2015 | 120 | 1.810 |
Why?
| Tuberculosis, Meningeal | 7 | 2016 | 11 | 1.780 |
Why?
| Vietnam | 50 | 2017 | 66 | 1.690 |
Why?
| Ribosomal Proteins | 9 | 2021 | 32 | 1.620 |
Why?
| Child, Preschool | 67 | 2021 | 4158 | 1.340 |
Why?
| Adolescent | 75 | 2022 | 6900 | 1.200 |
Why?
| Gene Expression Profiling | 11 | 2023 | 1141 | 1.110 |
Why?
| Child | 76 | 2024 | 7368 | 1.110 |
Why?
| Meningitis, Cryptococcal | 4 | 2016 | 12 | 1.080 |
Why?
| Infant | 53 | 2021 | 3829 | 1.080 |
Why?
| Humans | 144 | 2024 | 54391 | 1.010 |
Why?
| Research Support as Topic | 2 | 2015 | 51 | 0.980 |
Why?
| Adult | 73 | 2023 | 14207 | 0.930 |
Why?
| Influenza A Virus, H5N1 Subtype | 7 | 2015 | 7 | 0.900 |
Why?
| Young Adult | 54 | 2023 | 4318 | 0.900 |
Why?
| AIDS-Related Opportunistic Infections | 4 | 2017 | 41 | 0.890 |
Why?
| Dengue Virus | 9 | 2017 | 21 | 0.870 |
Why?
| Female | 85 | 2021 | 28471 | 0.830 |
Why?
| Rhabdomyosarcoma, Alveolar | 1 | 2021 | 9 | 0.820 |
Why?
| Li-Fraumeni Syndrome | 1 | 2021 | 13 | 0.820 |
Why?
| Male | 87 | 2022 | 27347 | 0.820 |
Why?
| Salmonella typhi | 7 | 2017 | 11 | 0.740 |
Why?
| Vaccines | 3 | 2022 | 65 | 0.730 |
Why?
| Antibodies, Viral | 11 | 2023 | 124 | 0.720 |
Why?
| Tumor Suppressor Protein p53 | 1 | 2021 | 251 | 0.720 |
Why?
| Endemic Diseases | 5 | 2017 | 29 | 0.710 |
Why?
| Polymorphism, Single Nucleotide | 13 | 2015 | 552 | 0.700 |
Why?
| Middle Aged | 52 | 2021 | 13082 | 0.680 |
Why?
| RNA, Viral | 12 | 2016 | 141 | 0.680 |
Why?
| Genetic Predisposition to Disease | 9 | 2015 | 570 | 0.670 |
Why?
| Dexamethasone | 5 | 2016 | 435 | 0.640 |
Why?
| Biomedical Research | 2 | 2014 | 241 | 0.630 |
Why?
| Antitubercular Agents | 3 | 2016 | 90 | 0.620 |
Why?
| Influenza A Virus, H1N1 Subtype | 6 | 2014 | 33 | 0.610 |
Why?
| Amphotericin B | 3 | 2017 | 122 | 0.610 |
Why?
| Communicable Diseases, Emerging | 3 | 2020 | 14 | 0.610 |
Why?
| Vaccination | 7 | 2023 | 298 | 0.600 |
Why?
| RNA Processing, Post-Transcriptional | 3 | 2014 | 29 | 0.600 |
Why?
| Disease Outbreaks | 5 | 2016 | 124 | 0.600 |
Why?
| Tuberculosis, Pulmonary | 3 | 2019 | 85 | 0.580 |
Why?
| Prognosis | 12 | 2023 | 2126 | 0.580 |
Why?
| Cryptococcus neoformans | 3 | 2016 | 28 | 0.540 |
Why?
| Rifampin | 1 | 2016 | 57 | 0.540 |
Why?
| GATA1 Transcription Factor | 2 | 2017 | 7 | 0.530 |
Why?
| RNA, Ribosomal | 1 | 2014 | 18 | 0.500 |
Why?
| Antifungal Agents | 3 | 2017 | 363 | 0.500 |
Why?
| RNA Precursors | 1 | 2014 | 11 | 0.500 |
Why?
| Drug Discovery | 1 | 2015 | 90 | 0.500 |
Why?
| Codon, Initiator | 1 | 2014 | 9 | 0.490 |
Why?
| Anti-Bacterial Agents | 6 | 2017 | 825 | 0.490 |
Why?
| Organizations | 1 | 2014 | 7 | 0.490 |
Why?
| Flucytosine | 2 | 2013 | 13 | 0.490 |
Why?
| Point Mutation | 1 | 2014 | 92 | 0.480 |
Why?
| Tetanus | 3 | 2013 | 8 | 0.470 |
Why?
| Mycobacterium tuberculosis | 4 | 2019 | 212 | 0.460 |
Why?
| Aged | 32 | 2022 | 10060 | 0.450 |
Why?
| Incidence | 14 | 2019 | 1083 | 0.430 |
Why?
| Breast Neoplasms | 1 | 2021 | 1249 | 0.420 |
Why?
| Hand, Foot and Mouth Disease | 3 | 2016 | 3 | 0.410 |
Why?
| Treatment Outcome | 16 | 2023 | 5612 | 0.400 |
Why?
| Amplified Fragment Length Polymorphism Analysis | 1 | 2010 | 2 | 0.390 |
Why?
| Mycological Typing Techniques | 1 | 2010 | 3 | 0.390 |
Why?
| Artemisinins | 2 | 2017 | 10 | 0.390 |
Why?
| Malaria, Falciparum | 2 | 2017 | 12 | 0.390 |
Why?
| HIV Infections | 5 | 2016 | 394 | 0.390 |
Why?
| DNA, Fungal | 1 | 2010 | 42 | 0.380 |
Why?
| Quinolines | 2 | 2017 | 40 | 0.380 |
Why?
| Antimalarials | 2 | 2017 | 30 | 0.380 |
Why?
| Gene Deletion | 1 | 2011 | 293 | 0.370 |
Why?
| Paratyphoid Fever | 3 | 2017 | 3 | 0.370 |
Why?
| Salmonella paratyphi A | 3 | 2017 | 3 | 0.370 |
Why?
| Ofloxacin | 3 | 2017 | 10 | 0.360 |
Why?
| Prospective Studies | 19 | 2022 | 2606 | 0.360 |
Why?
| Antibody Formation | 4 | 2022 | 69 | 0.360 |
Why?
| Azithromycin | 3 | 2017 | 42 | 0.360 |
Why?
| Fluoroquinolones | 5 | 2017 | 37 | 0.360 |
Why?
| Genotype | 10 | 2016 | 600 | 0.350 |
Why?
| Kaplan-Meier Estimate | 4 | 2016 | 514 | 0.350 |
Why?
| Cohort Studies | 10 | 2021 | 1546 | 0.340 |
Why?
| Central Nervous System Infections | 3 | 2013 | 8 | 0.330 |
Why?
| Salmonella enterica | 2 | 2006 | 18 | 0.330 |
Why?
| Genetic Variation | 4 | 2015 | 253 | 0.330 |
Why?
| World Health Organization | 2 | 2019 | 56 | 0.320 |
Why?
| Meningitis, Bacterial | 4 | 2012 | 9 | 0.320 |
Why?
| Influenza in Birds | 4 | 2014 | 5 | 0.310 |
Why?
| Oligonucleotide Array Sequence Analysis | 6 | 2011 | 474 | 0.310 |
Why?
| Severity of Illness Index | 7 | 2015 | 1082 | 0.300 |
Why?
| Induction Chemotherapy | 3 | 2017 | 59 | 0.300 |
Why?
| Nalidixic Acid | 1 | 2006 | 1 | 0.300 |
Why?
| Immunity, Innate | 4 | 2017 | 114 | 0.300 |
Why?
| DNA Methylation | 6 | 2023 | 575 | 0.300 |
Why?
| Cytokines | 3 | 2013 | 677 | 0.300 |
Why?
| Polymorphism, Genetic | 6 | 2012 | 193 | 0.300 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 10 | 2016 | 674 | 0.300 |
Why?
| Tumor Necrosis Factor-alpha | 3 | 2012 | 435 | 0.290 |
Why?
| Real-Time Polymerase Chain Reaction | 5 | 2013 | 206 | 0.290 |
Why?
| Epidemics | 2 | 2016 | 19 | 0.280 |
Why?
| Cardiovascular Diseases | 1 | 2012 | 476 | 0.280 |
Why?
| Oncogene Proteins, Fusion | 3 | 2021 | 60 | 0.280 |
Why?
| Molecular Sequence Data | 8 | 2013 | 980 | 0.280 |
Why?
| Phylogeny | 8 | 2016 | 269 | 0.270 |
Why?
| Pandemics | 3 | 2020 | 594 | 0.270 |
Why?
| Cooperative Behavior | 1 | 2007 | 253 | 0.270 |
Why?
| Microbial Sensitivity Tests | 7 | 2017 | 290 | 0.260 |
Why?
| Infant, Newborn | 12 | 2019 | 2923 | 0.260 |
Why?
| Disaster Planning | 2 | 2020 | 57 | 0.250 |
Why?
| Case-Control Studies | 8 | 2017 | 1229 | 0.250 |
Why?
| Aged, 80 and over | 11 | 2021 | 3431 | 0.250 |
Why?
| Drug Therapy, Combination | 3 | 2016 | 426 | 0.250 |
Why?
| Drug Resistance, Multiple, Bacterial | 3 | 2017 | 60 | 0.250 |
Why?
| Receptors, Cell Surface | 1 | 2005 | 130 | 0.240 |
Why?
| Streptococcus suis | 2 | 2015 | 11 | 0.240 |
Why?
| Age Distribution | 5 | 2014 | 199 | 0.240 |
Why?
| Respiratory Tract Infections | 2 | 2017 | 86 | 0.240 |
Why?
| Hemophilia A | 1 | 2024 | 28 | 0.240 |
Why?
| Cluster Analysis | 5 | 2013 | 249 | 0.240 |
Why?
| Membrane Glycoproteins | 1 | 2005 | 270 | 0.230 |
Why?
| Gene Rearrangement | 1 | 2024 | 76 | 0.230 |
Why?
| Osteosarcoma | 1 | 2023 | 37 | 0.230 |
Why?
| Chromosome Mapping | 5 | 2014 | 175 | 0.230 |
Why?
| Genome, Viral | 6 | 2016 | 100 | 0.220 |
Why?
| Cell Cycle Proteins | 2 | 2021 | 198 | 0.220 |
Why?
| Nepal | 8 | 2017 | 18 | 0.220 |
Why?
| Sesquiterpenes | 1 | 2004 | 91 | 0.220 |
Why?
| Population Surveillance | 3 | 2020 | 183 | 0.220 |
Why?
| Treatment Failure | 7 | 2017 | 141 | 0.220 |
Why?
| Prodrugs | 1 | 2022 | 33 | 0.220 |
Why?
| Proportional Hazards Models | 2 | 2016 | 430 | 0.220 |
Why?
| Encephalitis | 2 | 2013 | 48 | 0.220 |
Why?
| Viral Vaccines | 1 | 2022 | 14 | 0.220 |
Why?
| Anti-Infective Agents | 3 | 2020 | 111 | 0.220 |
Why?
| Critical Care | 1 | 2004 | 234 | 0.210 |
Why?
| Azacitidine | 2 | 2023 | 37 | 0.210 |
Why?
| Prevalence | 9 | 2020 | 1025 | 0.210 |
Why?
| Chromosome Aberrations | 3 | 2017 | 316 | 0.210 |
Why?
| Plasmodium falciparum | 2 | 2017 | 18 | 0.210 |
Why?
| Animals | 19 | 2023 | 14409 | 0.210 |
Why?
| Leukemia, Myelomonocytic, Juvenile | 1 | 2022 | 21 | 0.210 |
Why?
| Virology | 2 | 2012 | 9 | 0.200 |
Why?
| Phenotype | 4 | 2021 | 819 | 0.200 |
Why?
| Viral Nonstructural Proteins | 3 | 2010 | 61 | 0.200 |
Why?
| Neoplasms, Second Primary | 1 | 2022 | 77 | 0.200 |
Why?
| Anti-Inflammatory Agents | 3 | 2012 | 175 | 0.200 |
Why?
| Bone Neoplasms | 1 | 2023 | 193 | 0.200 |
Why?
| Co-Repressor Proteins | 1 | 2021 | 17 | 0.200 |
Why?
| Antigens, Viral | 2 | 2012 | 58 | 0.200 |
Why?
| Influenza A virus | 2 | 2014 | 18 | 0.200 |
Why?
| Recurrence | 3 | 2022 | 692 | 0.200 |
Why?
| Public Health Surveillance | 1 | 2020 | 13 | 0.200 |
Why?
| Chromosomal Proteins, Non-Histone | 1 | 2021 | 44 | 0.190 |
Why?
| Follow-Up Studies | 5 | 2020 | 2390 | 0.190 |
Why?
| Gene Regulatory Networks | 1 | 2021 | 124 | 0.190 |
Why?
| B-Lymphocytes | 1 | 2021 | 176 | 0.190 |
Why?
| Toll-Like Receptor 4 | 2 | 2012 | 51 | 0.190 |
Why?
| RNA, Messenger | 6 | 2021 | 1203 | 0.190 |
Why?
| Serologic Tests | 2 | 2020 | 28 | 0.190 |
Why?
| Sex Distribution | 3 | 2012 | 159 | 0.190 |
Why?
| International Cooperation | 1 | 2020 | 62 | 0.190 |
Why?
| Models, Biological | 3 | 2015 | 825 | 0.190 |
Why?
| Double-Blind Method | 4 | 2016 | 743 | 0.190 |
Why?
| Communicable Disease Control | 1 | 2020 | 39 | 0.180 |
Why?
| Leucine | 1 | 2020 | 113 | 0.180 |
Why?
| Chromatin | 1 | 2021 | 156 | 0.180 |
Why?
| Immunoglobulin G | 5 | 2022 | 227 | 0.180 |
Why?
| Drug Resistance, Bacterial | 3 | 2016 | 81 | 0.180 |
Why?
| Base Sequence | 6 | 2013 | 719 | 0.180 |
Why?
| Enterovirus A, Human | 2 | 2016 | 2 | 0.180 |
Why?
| Residence Characteristics | 1 | 2020 | 166 | 0.180 |
Why?
| Blood Transfusion | 1 | 2020 | 138 | 0.170 |
Why?
| Antibodies, Neutralizing | 2 | 2021 | 76 | 0.170 |
Why?
| Bacterial Proteins | 4 | 2012 | 456 | 0.170 |
Why?
| Enterovirus | 2 | 2016 | 9 | 0.170 |
Why?
| Antibodies, Bacterial | 2 | 2009 | 38 | 0.170 |
Why?
| MicroRNAs | 2 | 2021 | 386 | 0.170 |
Why?
| Zoonoses | 2 | 2020 | 18 | 0.170 |
Why?
| Ribosomes | 2 | 2009 | 33 | 0.170 |
Why?
| Transcriptome | 3 | 2017 | 346 | 0.170 |
Why?
| Drug Combinations | 3 | 2017 | 128 | 0.170 |
Why?
| Viral Load | 3 | 2021 | 86 | 0.170 |
Why?
| Hemorrhage | 3 | 2024 | 209 | 0.170 |
Why?
| Models, Statistical | 3 | 2014 | 259 | 0.160 |
Why?
| Research | 1 | 2019 | 117 | 0.160 |
Why?
| Research Report | 1 | 2018 | 16 | 0.160 |
Why?
| Sequence Analysis, DNA | 6 | 2016 | 274 | 0.160 |
Why?
| Geography | 6 | 2014 | 80 | 0.160 |
Why?
| Respiratory Mucosa | 1 | 2017 | 14 | 0.160 |
Why?
| Respiratory Syncytial Viruses | 1 | 2017 | 16 | 0.160 |
Why?
| Genomics | 3 | 2015 | 313 | 0.160 |
Why?
| DNA-Binding Proteins | 1 | 2021 | 462 | 0.160 |
Why?
| Hospitalization | 6 | 2017 | 704 | 0.160 |
Why?
| Respiratory Syncytial Virus Infections | 1 | 2017 | 37 | 0.160 |
Why?
| Blood Cells | 1 | 2017 | 58 | 0.160 |
Why?
| Talaromyces | 1 | 2017 | 1 | 0.160 |
Why?
| Chikungunya virus | 1 | 2017 | 2 | 0.150 |
Why?
| Encephalitis Virus, Japanese | 1 | 2017 | 2 | 0.150 |
Why?
| Deoxycholic Acid | 1 | 2017 | 17 | 0.150 |
Why?
| Meningoencephalitis | 1 | 2017 | 8 | 0.150 |
Why?
| Itraconazole | 1 | 2017 | 45 | 0.150 |
Why?
| Ribosome Subunits, Large, Eukaryotic | 2 | 2014 | 2 | 0.150 |
Why?
| Quality of Health Care | 1 | 2019 | 219 | 0.150 |
Why?
| Viremia | 3 | 2013 | 25 | 0.150 |
Why?
| X Chromosome | 1 | 1996 | 13 | 0.150 |
Why?
| Agammaglobulinemia | 1 | 1996 | 10 | 0.150 |
Why?
| Drug Resistance | 1 | 2017 | 75 | 0.150 |
Why?
| Genome, Human | 2 | 2021 | 131 | 0.150 |
Why?
| Pneumonia, Viral | 1 | 2020 | 184 | 0.150 |
Why?
| Disease Progression | 5 | 2015 | 915 | 0.140 |
Why?
| Molecular Epidemiology | 3 | 2010 | 36 | 0.140 |
Why?
| Receptors, Colony-Stimulating Factor | 1 | 2016 | 1 | 0.140 |
Why?
| Coronavirus Infections | 1 | 2020 | 192 | 0.140 |
Why?
| Molecular Diagnostic Techniques | 2 | 2017 | 40 | 0.140 |
Why?
| CCAAT-Enhancer-Binding Proteins | 1 | 2016 | 15 | 0.140 |
Why?
| Age Factors | 7 | 2015 | 1199 | 0.140 |
Why?
| HIV Protease Inhibitors | 1 | 2015 | 3 | 0.140 |
Why?
| Drug Resistance, Viral | 1 | 2015 | 8 | 0.140 |
Why?
| Enzyme-Linked Immunosorbent Assay | 6 | 2013 | 314 | 0.140 |
Why?
| Neutropenia | 1 | 1996 | 120 | 0.140 |
Why?
| Mycoses | 1 | 2017 | 162 | 0.140 |
Why?
| Cell Proliferation | 4 | 2021 | 1097 | 0.140 |
Why?
| Risk Assessment | 4 | 2015 | 1362 | 0.140 |
Why?
| Immunologic Factors | 2 | 2013 | 130 | 0.140 |
Why?
| Antiretroviral Therapy, Highly Active | 1 | 2015 | 40 | 0.140 |
Why?
| DNA Copy Number Variations | 1 | 2016 | 114 | 0.130 |
Why?
| HIV-1 | 1 | 2015 | 72 | 0.130 |
Why?
| Asia | 3 | 2014 | 32 | 0.130 |
Why?
| Time Factors | 5 | 2017 | 3210 | 0.130 |
Why?
| Mutation, Missense | 2 | 2013 | 117 | 0.130 |
Why?
| Antibodies | 1 | 2016 | 178 | 0.130 |
Why?
| Communicable Diseases | 1 | 2016 | 58 | 0.130 |
Why?
| Drug Industry | 1 | 2015 | 40 | 0.130 |
Why?
| DNA Gyrase | 2 | 2012 | 5 | 0.130 |
Why?
| Swine Diseases | 1 | 2015 | 16 | 0.130 |
Why?
| Registries | 1 | 2018 | 553 | 0.130 |
Why?
| HLA-DRB1 Chains | 1 | 2014 | 8 | 0.130 |
Why?
| Cambodia | 4 | 2017 | 4 | 0.130 |
Why?
| Killer Cells, Natural | 2 | 2013 | 106 | 0.130 |
Why?
| Hemagglutination | 1 | 2014 | 3 | 0.130 |
Why?
| Interferons | 1 | 2014 | 44 | 0.130 |
Why?
| Ribosome Subunits, Small, Eukaryotic | 1 | 2014 | 2 | 0.130 |
Why?
| Epoxide Hydrolases | 1 | 2015 | 49 | 0.130 |
Why?
| K562 Cells | 1 | 2014 | 47 | 0.130 |
Why?
| Signal Transduction | 4 | 2014 | 1752 | 0.130 |
Why?
| Polymerase Chain Reaction | 5 | 2021 | 531 | 0.120 |
Why?
| Streptococcal Infections | 1 | 2015 | 58 | 0.120 |
Why?
| Laboratory Personnel | 1 | 2014 | 1 | 0.120 |
Why?
| Typhoid-Paratyphoid Vaccines | 1 | 2014 | 1 | 0.120 |
Why?
| Genome-Wide Association Study | 2 | 2013 | 190 | 0.120 |
Why?
| Point-of-Care Systems | 2 | 2012 | 71 | 0.120 |
Why?
| Microbiology | 1 | 2014 | 11 | 0.120 |
Why?
| Access to Information | 1 | 2014 | 19 | 0.120 |
Why?
| Leukemia, Myeloid | 1 | 2014 | 54 | 0.120 |
Why?
| Shigella sonnei | 1 | 2013 | 1 | 0.120 |
Why?
| Survival Rate | 3 | 2012 | 954 | 0.120 |
Why?
| Disease Transmission, Infectious | 1 | 2014 | 19 | 0.120 |
Why?
| Reagent Kits, Diagnostic | 2 | 2010 | 22 | 0.120 |
Why?
| Hemagglutinin Glycoproteins, Influenza Virus | 1 | 2013 | 3 | 0.120 |
Why?
| Pharynx | 2 | 2012 | 39 | 0.120 |
Why?
| Virus Attachment | 1 | 2013 | 4 | 0.120 |
Why?
| Dysentery, Bacillary | 1 | 2013 | 4 | 0.120 |
Why?
| Anemia, Macrocytic | 1 | 2013 | 2 | 0.120 |
Why?
| Amino Acid Sequence | 3 | 2012 | 767 | 0.120 |
Why?
| Measles Vaccine | 1 | 2013 | 6 | 0.120 |
Why?
| Glucocorticoids | 1 | 2016 | 234 | 0.120 |
Why?
| Cross Infection | 2 | 2011 | 109 | 0.120 |
Why?
| Prednisolone | 1 | 2013 | 57 | 0.120 |
Why?
| Measles | 1 | 2013 | 9 | 0.120 |
Why?
| Circoviridae | 1 | 2013 | 1 | 0.120 |
Why?
| Circoviridae Infections | 1 | 2013 | 1 | 0.120 |
Why?
| Insect Vectors | 1 | 2013 | 5 | 0.120 |
Why?
| Hospitals, District | 1 | 2013 | 2 | 0.120 |
Why?
| Aedes | 1 | 2013 | 9 | 0.120 |
Why?
| Cytogenetic Analysis | 1 | 2013 | 90 | 0.120 |
Why?
| Phosphoinositide Phospholipase C | 1 | 2013 | 5 | 0.120 |
Why?
| Histocompatibility Antigens Class I | 1 | 2013 | 52 | 0.110 |
Why?
| Drug Resistance, Microbial | 1 | 2013 | 51 | 0.110 |
Why?
| Caliciviridae Infections | 1 | 2012 | 3 | 0.110 |
Why?
| Norovirus | 1 | 2012 | 4 | 0.110 |
Why?
| Multiplex Polymerase Chain Reaction | 1 | 2012 | 11 | 0.110 |
Why?
| Rotavirus Infections | 1 | 2012 | 7 | 0.110 |
Why?
| Rotavirus | 1 | 2012 | 10 | 0.110 |
Why?
| Information Dissemination | 1 | 2014 | 105 | 0.110 |
Why?
| Meningitis | 1 | 2012 | 24 | 0.110 |
Why?
| Climate | 1 | 2012 | 4 | 0.110 |
Why?
| Toll-Like Receptor 2 | 1 | 2012 | 29 | 0.110 |
Why?
| Infection Control | 1 | 2013 | 58 | 0.110 |
Why?
| Disasters | 1 | 2012 | 18 | 0.110 |
Why?
| Orthomyxoviridae | 1 | 2012 | 6 | 0.110 |
Why?
| Heart Function Tests | 1 | 2012 | 14 | 0.110 |
Why?
| Echocardiography, Doppler, Pulsed | 1 | 2012 | 10 | 0.110 |
Why?
| Plakophilins | 1 | 2012 | 2 | 0.110 |
Why?
| Mycobacterium Infections | 1 | 2012 | 12 | 0.110 |
Why?
| Receptors, Interleukin-1 | 1 | 2012 | 20 | 0.110 |
Why?
| Polysaccharides, Bacterial | 2 | 2009 | 19 | 0.110 |
Why?
| Haploinsufficiency | 1 | 2011 | 13 | 0.100 |
Why?
| Mosaicism | 1 | 2011 | 18 | 0.100 |
Why?
| Genotyping Techniques | 1 | 2011 | 26 | 0.100 |
Why?
| Heart Defects, Congenital | 1 | 2018 | 608 | 0.100 |
Why?
| Chromosome Deletion | 2 | 2013 | 150 | 0.100 |
Why?
| Blotting, Northern | 1 | 2011 | 108 | 0.100 |
Why?
| Encephalitis, Japanese | 2 | 2017 | 3 | 0.100 |
Why?
| Adrenal Cortex Hormones | 1 | 2012 | 95 | 0.100 |
Why?
| Patient Positioning | 1 | 2011 | 35 | 0.100 |
Why?
| Echocardiography, Doppler | 1 | 2012 | 61 | 0.100 |
Why?
| Intracellular Signaling Peptides and Proteins | 1 | 2012 | 151 | 0.100 |
Why?
| Tuberculosis | 1 | 2012 | 104 | 0.100 |
Why?
| Thrombocytopenia | 1 | 2012 | 99 | 0.100 |
Why?
| Poultry | 4 | 2014 | 29 | 0.100 |
Why?
| CD8-Positive T-Lymphocytes | 1 | 2012 | 116 | 0.100 |
Why?
| Spironolactone | 1 | 2010 | 5 | 0.100 |
Why?
| Stroke Volume | 1 | 2012 | 151 | 0.100 |
Why?
| Altitude Sickness | 1 | 2010 | 8 | 0.100 |
Why?
| Gastrointestinal Tract | 1 | 2012 | 136 | 0.100 |
Why?
| Ventricular Dysfunction, Left | 1 | 2012 | 99 | 0.100 |
Why?
| Methicillin-Resistant Staphylococcus aureus | 2 | 2013 | 88 | 0.100 |
Why?
| RNA, Small Interfering | 2 | 2008 | 253 | 0.100 |
Why?
| Asia, Southeastern | 2 | 2007 | 11 | 0.100 |
Why?
| Risk Factors | 7 | 2015 | 3937 | 0.100 |
Why?
| Child, Hospitalized | 1 | 2011 | 34 | 0.100 |
Why?
| Haplotypes | 2 | 2010 | 105 | 0.100 |
Why?
| Neoplastic Stem Cells | 2 | 2022 | 104 | 0.100 |
Why?
| Pneumonia | 1 | 2011 | 129 | 0.090 |
Why?
| Influenza A Virus, H3N2 Subtype | 1 | 2010 | 4 | 0.090 |
Why?
| China | 3 | 2016 | 104 | 0.090 |
Why?
| Bacterial Typing Techniques | 1 | 2010 | 32 | 0.090 |
Why?
| Nasopharynx | 1 | 2010 | 32 | 0.090 |
Why?
| Daunorubicin | 2 | 2022 | 12 | 0.090 |
Why?
| Blood Proteins | 1 | 2010 | 100 | 0.090 |
Why?
| Nasal Mucosa | 1 | 2010 | 22 | 0.090 |
Why?
| WT1 Proteins | 1 | 2009 | 5 | 0.090 |
Why?
| Radiography | 2 | 2009 | 526 | 0.090 |
Why?
| Cytarabine | 2 | 2022 | 40 | 0.090 |
Why?
| Sepsis | 1 | 2013 | 250 | 0.090 |
Why?
| Reassortant Viruses | 1 | 2009 | 5 | 0.090 |
Why?
| Blood Bactericidal Activity | 1 | 2009 | 6 | 0.090 |
Why?
| Cell Differentiation | 3 | 2021 | 720 | 0.090 |
Why?
| DNA, Bacterial | 1 | 2010 | 172 | 0.090 |
Why?
| Critical Illness | 1 | 2013 | 344 | 0.090 |
Why?
| Electrocardiography | 1 | 2012 | 290 | 0.090 |
Why?
| Practice Guidelines as Topic | 1 | 2013 | 489 | 0.090 |
Why?
| Comorbidity | 1 | 2012 | 664 | 0.090 |
Why?
| Neutrophils | 1 | 2010 | 154 | 0.090 |
Why?
| Pilot Projects | 2 | 2020 | 807 | 0.090 |
Why?
| Serotyping | 3 | 2014 | 15 | 0.090 |
Why?
| Membrane Proteins | 1 | 2012 | 389 | 0.090 |
Why?
| Sensitivity and Specificity | 4 | 2012 | 922 | 0.080 |
Why?
| Tracheostomy | 2 | 2011 | 81 | 0.080 |
Why?
| Chromosomes, Human, Pair 3 | 1 | 2008 | 20 | 0.080 |
Why?
| Gene Expression Regulation | 2 | 2014 | 1063 | 0.080 |
Why?
| Pedigree | 1 | 2008 | 146 | 0.080 |
Why?
| Ethics Committees, Research | 1 | 2007 | 18 | 0.080 |
Why?
| Toll-Like Receptor 1 | 1 | 2007 | 2 | 0.080 |
Why?
| Leukocidins | 1 | 2007 | 8 | 0.080 |
Why?
| Exotoxins | 1 | 2007 | 9 | 0.080 |
Why?
| Saccharomyces cerevisiae Proteins | 1 | 2009 | 170 | 0.080 |
Why?
| Bacterial Vaccines | 1 | 2007 | 16 | 0.080 |
Why?
| Chromosomes, Human, Pair 6 | 1 | 2007 | 15 | 0.080 |
Why?
| Cefixime | 1 | 2007 | 5 | 0.080 |
Why?
| Wilms Tumor | 1 | 2007 | 17 | 0.080 |
Why?
| Genetic Association Studies | 2 | 2021 | 136 | 0.080 |
Why?
| Telemedicine | 1 | 2014 | 453 | 0.080 |
Why?
| Attitude of Health Personnel | 1 | 2011 | 390 | 0.080 |
Why?
| Cross-Sectional Studies | 5 | 2015 | 1696 | 0.080 |
Why?
| Mebendazole | 1 | 2007 | 3 | 0.080 |
Why?
| Community-Acquired Infections | 1 | 2007 | 42 | 0.080 |
Why?
| Hookworm Infections | 1 | 2007 | 2 | 0.080 |
Why?
| Lipoproteins | 1 | 2007 | 45 | 0.080 |
Why?
| Linkage Disequilibrium | 1 | 2007 | 47 | 0.080 |
Why?
| Seasons | 3 | 2014 | 98 | 0.080 |
Why?
| Transcription Factors | 2 | 2021 | 622 | 0.080 |
Why?
| Bacterial Toxins | 1 | 2007 | 61 | 0.080 |
Why?
| Genes, Tumor Suppressor | 1 | 2007 | 85 | 0.070 |
Why?
| Ascariasis | 1 | 2006 | 4 | 0.070 |
Why?
| Blood Cell Count | 1 | 2006 | 43 | 0.070 |
Why?
| Ubiquitin-Protein Ligases | 1 | 2007 | 100 | 0.070 |
Why?
| Helminthiasis | 1 | 2006 | 4 | 0.070 |
Why?
| Consensus | 1 | 2007 | 157 | 0.070 |
Why?
| DNA Helicases | 1 | 2008 | 132 | 0.070 |
Why?
| Sanitation | 1 | 2006 | 20 | 0.070 |
Why?
| Dermatitis, Allergic Contact | 1 | 2006 | 18 | 0.070 |
Why?
| Respiration, Artificial | 2 | 2011 | 286 | 0.070 |
Why?
| Hospitals | 3 | 2012 | 188 | 0.070 |
Why?
| Promoter Regions, Genetic | 3 | 2017 | 520 | 0.070 |
Why?
| Family | 1 | 2007 | 191 | 0.070 |
Why?
| Mice | 4 | 2023 | 6428 | 0.070 |
Why?
| Protein Binding | 2 | 2021 | 736 | 0.070 |
Why?
| Kidney Neoplasms | 1 | 2007 | 197 | 0.070 |
Why?
| Flagellin | 1 | 2005 | 4 | 0.070 |
Why?
| Toll-Like Receptor 5 | 1 | 2005 | 5 | 0.070 |
Why?
| Toll-Like Receptors | 1 | 2005 | 25 | 0.070 |
Why?
| Tacrolimus | 1 | 2005 | 52 | 0.070 |
Why?
| Graft vs Host Disease | 1 | 2005 | 84 | 0.060 |
Why?
| Cell Line | 1 | 2008 | 1152 | 0.060 |
Why?
| Basic Reproduction Number | 2 | 2015 | 2 | 0.060 |
Why?
| Disease Models, Animal | 3 | 2021 | 1647 | 0.060 |
Why?
| Models, Genetic | 2 | 2017 | 209 | 0.060 |
Why?
| Autoimmune Diseases | 1 | 2005 | 115 | 0.060 |
Why?
| DNA | 1 | 2008 | 581 | 0.060 |
Why?
| Chemokines | 1 | 2004 | 96 | 0.060 |
Why?
| Immunoglobulin M | 3 | 2010 | 65 | 0.060 |
Why?
| Factor VIII | 1 | 2024 | 29 | 0.060 |
Why?
| Acute Disease | 2 | 2017 | 403 | 0.060 |
Why?
| Trimethoprim | 1 | 2004 | 4 | 0.060 |
Why?
| Myeloid-Lymphoid Leukemia Protein | 1 | 2024 | 16 | 0.060 |
Why?
| Proto-Oncogenes | 1 | 2024 | 29 | 0.060 |
Why?
| Genetic Testing | 1 | 2005 | 135 | 0.060 |
Why?
| Drug Resistance, Multiple | 1 | 2004 | 20 | 0.060 |
Why?
| Staphylococcal Infections | 1 | 2007 | 302 | 0.060 |
Why?
| Leukotriene A4 | 2 | 2015 | 2 | 0.060 |
Why?
| T-Lymphocytes | 1 | 2006 | 374 | 0.060 |
Why?
| Administration, Oral | 2 | 2017 | 461 | 0.060 |
Why?
| Retinoblastoma-Binding Protein 2 | 1 | 2023 | 6 | 0.060 |
Why?
| Nuclear Pore Complex Proteins | 1 | 2023 | 9 | 0.060 |
Why?
| Proto-Oncogene Proteins c-ret | 1 | 2024 | 35 | 0.060 |
Why?
| Flow Cytometry | 1 | 2006 | 547 | 0.060 |
Why?
| Ciprofloxacin | 2 | 2013 | 28 | 0.060 |
Why?
| Autoantibodies | 1 | 2024 | 135 | 0.060 |
Why?
| Regression Analysis | 2 | 2014 | 445 | 0.060 |
Why?
| Netherlands | 2 | 2014 | 22 | 0.060 |
Why?
| Placebos | 2 | 2013 | 90 | 0.060 |
Why?
| CpG Islands | 1 | 2023 | 104 | 0.060 |
Why?
| Lymphocyte Count | 2 | 2013 | 23 | 0.060 |
Why?
| Carboxylesterase | 1 | 2022 | 5 | 0.060 |
Why?
| Carboxylic Ester Hydrolases | 1 | 2022 | 6 | 0.060 |
Why?
| Logistic Models | 2 | 2016 | 991 | 0.060 |
Why?
| Proto-Oncogene Proteins c-cbl | 1 | 2022 | 3 | 0.050 |
Why?
| Core Binding Factor beta Subunit | 1 | 2021 | 4 | 0.050 |
Why?
| Myosin Heavy Chains | 1 | 2021 | 19 | 0.050 |
Why?
| Genes, Viral | 2 | 2012 | 43 | 0.050 |
Why?
| Odds Ratio | 2 | 2014 | 600 | 0.050 |
Why?
| Open Reading Frames | 2 | 2012 | 55 | 0.050 |
Why?
| Selection, Genetic | 2 | 2012 | 27 | 0.050 |
Why?
| Apoptosis | 1 | 2008 | 1302 | 0.050 |
Why?
| Evolution, Molecular | 2 | 2013 | 103 | 0.050 |
Why?
| Microsomes, Liver | 1 | 2022 | 214 | 0.050 |
Why?
| RNA | 1 | 2022 | 202 | 0.050 |
Why?
| Immunoassay | 2 | 2012 | 31 | 0.050 |
Why?
| Bayes Theorem | 1 | 2021 | 125 | 0.050 |
Why?
| Alleles | 2 | 2014 | 277 | 0.050 |
Why?
| Gene Expression Regulation, Leukemic | 1 | 2021 | 36 | 0.050 |
Why?
| Antiviral Agents | 3 | 2009 | 188 | 0.050 |
Why?
| England | 1 | 2020 | 61 | 0.050 |
Why?
| Acetylation | 1 | 2021 | 99 | 0.050 |
Why?
| Enhancer Elements, Genetic | 1 | 2021 | 64 | 0.050 |
Why?
| Models, Theoretical | 2 | 2014 | 184 | 0.050 |
Why?
| Intensive Care Units | 2 | 2013 | 232 | 0.050 |
Why?
| RNA-Binding Proteins | 1 | 2021 | 136 | 0.050 |
Why?
| Weather | 1 | 2020 | 7 | 0.050 |
Why?
| Trans-Activators | 1 | 2021 | 147 | 0.050 |
Why?
| Diarrhea | 2 | 2012 | 90 | 0.050 |
Why?
| Gene Frequency | 2 | 2012 | 120 | 0.050 |
Why?
| Gene Knockdown Techniques | 2 | 2012 | 125 | 0.050 |
Why?
| HEK293 Cells | 1 | 2021 | 245 | 0.050 |
Why?
| Climate Change | 1 | 2020 | 27 | 0.050 |
Why?
| Mice, Inbred BALB C | 1 | 2021 | 370 | 0.050 |
Why?
| Interdisciplinary Communication | 1 | 2020 | 64 | 0.050 |
Why?
| Receptors, GABA-A | 1 | 2019 | 16 | 0.050 |
Why?
| Cell Transformation, Neoplastic | 1 | 2021 | 200 | 0.040 |
Why?
| Up-Regulation | 1 | 2021 | 509 | 0.040 |
Why?
| Anticoagulants | 1 | 2022 | 270 | 0.040 |
Why?
| Health Surveys | 1 | 2020 | 261 | 0.040 |
Why?
| Forecasting | 1 | 2020 | 161 | 0.040 |
Why?
| Models, Animal | 1 | 2020 | 255 | 0.040 |
Why?
| Political Systems | 1 | 2019 | 2 | 0.040 |
Why?
| Disease Eradication | 1 | 2019 | 3 | 0.040 |
Why?
| Health Priorities | 1 | 2019 | 19 | 0.040 |
Why?
| Feasibility Studies | 1 | 2020 | 398 | 0.040 |
Why?
| Hematopoietic Stem Cells | 1 | 2021 | 215 | 0.040 |
Why?
| Goals | 1 | 2019 | 49 | 0.040 |
Why?
| Inflammation | 2 | 2015 | 678 | 0.040 |
Why?
| Cell Line, Tumor | 1 | 2023 | 1551 | 0.040 |
Why?
| Mortality | 1 | 2019 | 102 | 0.040 |
Why?
| Histones | 1 | 2021 | 335 | 0.040 |
Why?
| Combined Modality Therapy | 1 | 2020 | 693 | 0.040 |
Why?
| Cost of Illness | 1 | 2019 | 132 | 0.040 |
Why?
| Oxidative Stress | 1 | 2024 | 958 | 0.040 |
Why?
| Common Cold | 1 | 2017 | 6 | 0.040 |
Why?
| Leadership | 1 | 2019 | 114 | 0.040 |
Why?
| Health Policy | 1 | 2019 | 171 | 0.040 |
Why?
| Orientia tsutsugamushi | 1 | 2017 | 1 | 0.040 |
Why?
| Scrub Typhus | 1 | 2017 | 1 | 0.040 |
Why?
| Etoposide | 1 | 2017 | 86 | 0.040 |
Why?
| Ceftriaxone | 1 | 2017 | 29 | 0.040 |
Why?
| Erythroid Cells | 1 | 2017 | 5 | 0.040 |
Why?
| Genes, Dominant | 1 | 2017 | 21 | 0.040 |
Why?
| Erythropoiesis | 1 | 2017 | 19 | 0.040 |
Why?
| Genes, X-Linked | 1 | 2017 | 8 | 0.040 |
Why?
| Creatinine | 1 | 2017 | 169 | 0.040 |
Why?
| Lost to Follow-Up | 1 | 2016 | 11 | 0.040 |
Why?
| Reproducibility of Results | 2 | 2012 | 1301 | 0.040 |
Why?
| Mass Screening | 1 | 2020 | 370 | 0.040 |
Why?
| Infusions, Intravenous | 1 | 2017 | 231 | 0.040 |
Why?
| Spinal Puncture | 1 | 2016 | 20 | 0.040 |
Why?
| Oxygen | 2 | 2010 | 361 | 0.040 |
Why?
| Hydrocephalus | 1 | 2016 | 42 | 0.040 |
Why?
| Cerebrospinal Fluid Pressure | 1 | 2016 | 4 | 0.040 |
Why?
| Protein-Tyrosine Kinases | 1 | 1996 | 101 | 0.040 |
Why?
| Colony Count, Microbial | 1 | 2016 | 66 | 0.030 |
Why?
| Cerebrospinal Fluid | 1 | 2016 | 36 | 0.030 |
Why?
| Specimen Handling | 1 | 2016 | 62 | 0.030 |
Why?
| Sus scrofa | 1 | 2015 | 39 | 0.030 |
Why?
| Antigen Presentation | 1 | 2014 | 28 | 0.030 |
Why?
| Hemagglutination Inhibition Tests | 1 | 2014 | 4 | 0.030 |
Why?
| Family Health | 1 | 2015 | 85 | 0.030 |
Why?
| Principal Component Analysis | 1 | 2014 | 71 | 0.030 |
Why?
| Biosurveillance | 1 | 2014 | 2 | 0.030 |
Why?
| Ubiquitination | 1 | 2014 | 47 | 0.030 |
Why?
| Genetic Markers | 1 | 2014 | 117 | 0.030 |
Why?
| Rain | 1 | 2014 | 6 | 0.030 |
Why?
| Virulence Factors | 1 | 2015 | 94 | 0.030 |
Why?
| Commerce | 1 | 2014 | 47 | 0.030 |
Why?
| Carrier State | 1 | 2014 | 12 | 0.030 |
Why?
| Epigenesis, Genetic | 1 | 2017 | 399 | 0.030 |
Why?
| Methylation | 1 | 2014 | 130 | 0.030 |
Why?
| Chromosomes, Bacterial | 1 | 2013 | 17 | 0.030 |
Why?
| Mutation Rate | 1 | 2013 | 40 | 0.030 |
Why?
| Receptors, Virus | 1 | 2013 | 30 | 0.030 |
Why?
| Hygiene | 1 | 2013 | 19 | 0.030 |
Why?
| Rural Population | 2 | 2010 | 598 | 0.030 |
Why?
| Water Supply | 1 | 2013 | 21 | 0.030 |
Why?
| Chromosomes, Human, Pair 5 | 1 | 2013 | 16 | 0.030 |
Why?
| Swine | 1 | 2015 | 430 | 0.030 |
Why?
| Immunomodulation | 1 | 2013 | 42 | 0.030 |
Why?
| T-Lymphocytes, Cytotoxic | 1 | 2013 | 72 | 0.030 |
Why?
| Mutant Proteins | 1 | 2013 | 41 | 0.030 |
Why?
| Education, Distance | 1 | 2014 | 39 | 0.030 |
Why?
| Likelihood Functions | 1 | 2013 | 61 | 0.030 |
Why?
| Multivariate Analysis | 1 | 2015 | 643 | 0.030 |
Why?
| Crystallography, X-Ray | 1 | 2013 | 178 | 0.030 |
Why?
| Ceftazidime | 1 | 2013 | 9 | 0.030 |
Why?
| Length of Stay | 1 | 2016 | 683 | 0.030 |
Why?
| Food Supply | 1 | 2014 | 101 | 0.030 |
Why?
| Piperacillin | 1 | 2013 | 25 | 0.030 |
Why?
| Penicillanic Acid | 1 | 2013 | 23 | 0.030 |
Why?
| Protein Conformation | 1 | 2013 | 226 | 0.030 |
Why?
| Cells, Cultured | 1 | 2017 | 1737 | 0.030 |
Why?
| Proteus | 1 | 2012 | 1 | 0.030 |
Why?
| Pantoea | 1 | 2012 | 1 | 0.030 |
Why?
| Citrobacter | 1 | 2012 | 2 | 0.030 |
Why?
| Klebsiella | 1 | 2012 | 5 | 0.030 |
Why?
| Shigella | 1 | 2012 | 7 | 0.030 |
Why?
| Enterobacteriaceae | 1 | 2012 | 11 | 0.030 |
Why?
| Gram-Negative Bacteria | 1 | 2013 | 37 | 0.030 |
Why?
| Gastroenteritis | 1 | 2012 | 20 | 0.030 |
Why?
| Computational Biology | 1 | 2014 | 231 | 0.030 |
Why?
| DNA, Viral | 1 | 2013 | 143 | 0.030 |
Why?
| Meningitis, Viral | 1 | 2012 | 2 | 0.030 |
Why?
| Encephalitis, Viral | 1 | 2012 | 6 | 0.030 |
Why?
| Genome, Bacterial | 1 | 2013 | 141 | 0.030 |
Why?
| Gentian Violet | 1 | 2012 | 6 | 0.030 |
Why?
| Phenazines | 1 | 2012 | 4 | 0.030 |
Why?
| Malawi | 1 | 2012 | 11 | 0.030 |
Why?
| Single-Blind Method | 1 | 2012 | 120 | 0.030 |
Why?
| Lymphocyte Subsets | 1 | 2012 | 13 | 0.030 |
Why?
| Leukotriene B4 | 1 | 2012 | 2 | 0.030 |
Why?
| Tropical Climate | 1 | 2012 | 10 | 0.030 |
Why?
| Mycobacterium marinum | 1 | 2012 | 4 | 0.030 |
Why?
| Lipoxins | 1 | 2012 | 4 | 0.030 |
Why?
| Glasgow Coma Scale | 1 | 2012 | 48 | 0.030 |
Why?
| Leukocyte Count | 1 | 2012 | 77 | 0.030 |
Why?
| Phospholipid Transfer Proteins | 1 | 2012 | 3 | 0.030 |
Why?
| Nose | 1 | 2012 | 42 | 0.030 |
Why?
| Seroepidemiologic Studies | 1 | 2012 | 50 | 0.030 |
Why?
| Plasmids | 1 | 2012 | 180 | 0.030 |
Why?
| Feces | 1 | 2012 | 137 | 0.030 |
Why?
| Zebrafish | 1 | 2012 | 58 | 0.030 |
Why?
| Host-Pathogen Interactions | 1 | 2013 | 143 | 0.030 |
Why?
| Monocytes | 1 | 2012 | 156 | 0.030 |
Why?
| Quantitative Trait, Heritable | 1 | 2011 | 30 | 0.030 |
Why?
| ROC Curve | 1 | 2012 | 259 | 0.020 |
Why?
| Lymphocyte Activation | 1 | 2012 | 197 | 0.020 |
Why?
| Health Behavior | 1 | 2013 | 275 | 0.020 |
Why?
| Mountaineering | 1 | 2010 | 3 | 0.020 |
Why?
| Thalidomide | 1 | 2013 | 398 | 0.020 |
Why?
| Risk | 1 | 2012 | 343 | 0.020 |
Why?
| Population Density | 1 | 2010 | 21 | 0.020 |
Why?
| Neutrophil Activation | 1 | 2010 | 10 | 0.020 |
Why?
| Socioeconomic Factors | 1 | 2013 | 639 | 0.020 |
Why?
| Acetazolamide | 1 | 2010 | 20 | 0.020 |
Why?
| Cryptococcus gattii | 1 | 2010 | 1 | 0.020 |
Why?
| Health Facilities | 1 | 2010 | 43 | 0.020 |
Why?
| Viral Matrix Proteins | 1 | 2010 | 7 | 0.020 |
Why?
| Headache | 1 | 2010 | 78 | 0.020 |
Why?
| Escherichia coli | 1 | 2012 | 250 | 0.020 |
Why?
| Species Specificity | 1 | 2010 | 206 | 0.020 |
Why?
| Focus Groups | 1 | 2011 | 207 | 0.020 |
Why?
| High-Throughput Screening Assays | 1 | 2010 | 37 | 0.020 |
Why?
| Referral and Consultation | 1 | 2012 | 308 | 0.020 |
Why?
| Transcription, Genetic | 1 | 2012 | 418 | 0.020 |
Why?
| Heart Rate | 1 | 2012 | 358 | 0.020 |
Why?
| Algorithms | 1 | 2014 | 697 | 0.020 |
Why?
| Transaminases | 1 | 2009 | 14 | 0.020 |
Why?
| Oseltamivir | 1 | 2009 | 7 | 0.020 |
Why?
| Immunity, Humoral | 1 | 2009 | 25 | 0.020 |
Why?
| Lymphopenia | 1 | 2009 | 21 | 0.020 |
Why?
| Longitudinal Studies | 1 | 2012 | 742 | 0.020 |
Why?
| Interleukin-8 | 1 | 2009 | 99 | 0.020 |
Why?
| Antigens, Bacterial | 1 | 2009 | 63 | 0.020 |
Why?
| Urban Population | 1 | 2010 | 182 | 0.020 |
Why?
| Fetal Blood | 1 | 2009 | 67 | 0.020 |
Why?
| Sex Factors | 1 | 2012 | 766 | 0.020 |
Why?
| Interleukin-10 | 1 | 2009 | 106 | 0.020 |
Why?
| Exons | 1 | 2009 | 105 | 0.020 |
Why?
| Retroviridae | 1 | 2008 | 10 | 0.020 |
Why?
| Predictive Value of Tests | 1 | 2012 | 1045 | 0.020 |
Why?
| Anaerobiosis | 1 | 2008 | 15 | 0.020 |
Why?
| Transduction, Genetic | 1 | 2008 | 50 | 0.020 |
Why?
| Disease-Free Survival | 1 | 2009 | 488 | 0.020 |
Why?
| Statistics, Nonparametric | 1 | 2009 | 232 | 0.020 |
Why?
| DNA Mutational Analysis | 1 | 2009 | 217 | 0.020 |
Why?
| Protein Structure, Tertiary | 1 | 2009 | 289 | 0.020 |
Why?
| Computer Simulation | 1 | 2009 | 332 | 0.020 |
Why?
| Interleukin-6 | 1 | 2009 | 315 | 0.020 |
Why?
| Ankyrin Repeat | 1 | 2007 | 2 | 0.020 |
Why?
| Electrophoresis, Gel, Pulsed-Field | 1 | 2007 | 28 | 0.020 |
Why?
| Mitochondria | 1 | 2012 | 490 | 0.020 |
Why?
| Retrospective Studies | 2 | 2011 | 6459 | 0.020 |
Why?
| Mice, Mutant Strains | 1 | 2007 | 84 | 0.020 |
Why?
| Salmonella Infections | 1 | 2007 | 15 | 0.020 |
Why?
| Salmonella | 1 | 2007 | 25 | 0.020 |
Why?
| Albendazole | 1 | 2007 | 9 | 0.020 |
Why?
| Immunoblotting | 1 | 2007 | 134 | 0.020 |
Why?
| Analysis of Variance | 1 | 2009 | 634 | 0.020 |
Why?
| Anthelmintics | 1 | 2007 | 11 | 0.020 |
Why?
| Fluorescent Antibody Technique | 1 | 2007 | 141 | 0.020 |
Why?
| Mites | 1 | 2006 | 3 | 0.020 |
Why?
| Antibodies, Monoclonal | 1 | 2012 | 564 | 0.020 |
Why?
| Cockroaches | 1 | 2006 | 6 | 0.020 |
Why?
| Dust | 1 | 2006 | 25 | 0.020 |
Why?
| Randomized Controlled Trials as Topic | 1 | 2010 | 594 | 0.020 |
Why?
| Transfection | 1 | 2007 | 399 | 0.020 |
Why?
| Immunization | 1 | 2006 | 95 | 0.020 |
Why?
| Fibroblasts | 1 | 2008 | 386 | 0.020 |
Why?
| Primary Health Care | 1 | 2010 | 398 | 0.020 |
Why?
| Absorption | 1 | 2005 | 24 | 0.020 |
Why?
| Magnetic Resonance Imaging | 1 | 2013 | 1616 | 0.020 |
Why?
| Administration, Topical | 1 | 2005 | 71 | 0.020 |
Why?
| Lung | 1 | 2009 | 508 | 0.020 |
Why?
| Allergens | 1 | 2006 | 147 | 0.020 |
Why?
| NF-kappa B | 1 | 2007 | 336 | 0.020 |
Why?
| Influenza Vaccines | 1 | 2005 | 42 | 0.020 |
Why?
| Bone Marrow Transplantation | 1 | 2005 | 149 | 0.020 |
Why?
| CD4 Lymphocyte Count | 1 | 2004 | 35 | 0.020 |
Why?
| Chemokine CCL5 | 1 | 2004 | 5 | 0.020 |
Why?
| Brain | 1 | 2013 | 1392 | 0.020 |
Why?
| Interleukins | 1 | 2004 | 39 | 0.020 |
Why?
| Interferon-alpha | 1 | 2004 | 50 | 0.020 |
Why?
| Virus Replication | 1 | 2005 | 143 | 0.020 |
Why?
| Skin Diseases | 1 | 2005 | 141 | 0.010 |
Why?
| Interferon-gamma | 1 | 2004 | 195 | 0.010 |
Why?
| Gene Expression Regulation, Neoplastic | 1 | 2007 | 868 | 0.010 |
Why?
| Nitric Oxide | 1 | 2004 | 298 | 0.010 |
Why?
| Pregnancy | 1 | 2009 | 2639 | 0.010 |
Why?
|
|
Farrar's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|